News
-
-
PRESS RELEASE
BioNxt Announces Closing of Shares for Debt Settlement
BioNxt Solutions Inc. settles $2.7M debt with 6,008,883 common shares. Compensation shares issued to Canaccord Genuity Corp. for facilitating the debt settlement. Company focuses on drug delivery tech and pharmaceutical development -
-
PRESS RELEASE
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
BioNxt Solutions Inc. receives European Patent No. 4539857 for sublingual cladribine oral thin film drug delivery tech, advancing global IP rights in pharmaceutical sector -
-
-
-
PRESS RELEASE
BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion
BioNxt announces progress in cladribine oral thin film development, with focus on bioavailability improvement and human clinical study for Multiple Sclerosis. Expansion into Myasthenia Gravis also planned -
-
PRESS RELEASE
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)
BioNxt reports successful preclinical study results for sublingual oral dissolvable film (ODF) cladribine formulation in treating Multiple Sclerosis (MS), achieving higher systemic drug delivery than oral tablets
